## Drug Summary
Pegaspargase, marketed under the name Oncaspar, is a pegylated pharmaceutical agent used primarily as part of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) in both pediatric and adult patients. It is particularly useful for individuals who show hypersensitivity to native forms of L-asparaginase, another enzyme-based drug derived from *Escherichia coli*. Pegaspargase works by depleting the amino acid asparagine, which is essential for the growth of leukemic cells but not for most normal cells. These leukemia cells lack asparagine synthetase and cannot synthesize asparagine autonomously. Pegylating the enzyme extends its half-life in the blood and reduces the immune response it might otherwise provoke. The drug has a notable pharmacokinetic profile with extended activity allowing infrequent dosing, but can lead to side effects such as thrombosis and pancreatitis.

## Drug Targets, Enzymes, Transporters, and Carriers
Pegaspargase is a modified version of L-asparaginase, which catalyzes the conversion of asparagine into aspartic acid and ammonia, leading to the starvation of rapidly proliferating leukemic cells. Pegaspargase itself does not have any specific listed drug targets except its substrate, asparagine. Once administered, it is metabolized by proteolytic enzymes distributed across different body tissues. The details of specific transporters or enzymes largely influencing its activity or metabolism arenâ€™t explicitly documented in the provided data. However, it has been found to bind to Thyroxine-binding globulin (SERPINA7), which may influence its distribution or function. 

## Pharmacogenetics
As of the supplied data and general knowledge, specific pharmacogenetic markers that predict the response to Pegaspargase have not been established. However, the genetic basis of hypersensitivity reactions, commonly observed in other asparaginase preparations from *E. coli* or *Erwinia chrysanthemi*, suggests that genetic predispositions could influence therapy outcomes and adverse reactions. These reactions might involve complex genetic interactions including those genes involved in immune system function. Future research could potentially identify genetic predictors of efficacy and safety for Pegaspargase, which could lead to more personalized approaches in managing ALL. Given the mechanism and metabolism of the drug, variants in genes encoding proteolytic enzymes or proteins involved in inflammatory and immune responses could be potential areas of interest for pharmacogenetic studies.